Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation - Narrative (Details)

v3.23.3
Stock-Based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended
Mar. 20, 2023
Sep. 30, 2023
Omnibus incentive plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized to issue (in shares)   14,200,000
Available for issuance (in shares)   7,900,000
Number of options granted (in shares)   46,081
Weighted-average grant date fair value for options granted (in dollars per share)   $ 3.96
Time Vesting, Options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Compensation expense not yet recognized   $ 4.9
Compensation expense not yet recognized, weighted-average period   2 years 2 months 12 days
Options | Omnibus incentive plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Compensation expense not yet recognized   $ 4.9
Compensation expense not yet recognized, weighted-average period   2 years 2 months 12 days
Restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Compensation expense not yet recognized   $ 31.2
Compensation expense not yet recognized, weighted-average period   2 years 4 months 24 days
Granted in period (in shares)   3,389,064
Granted, weighted average grant date fair value (in dollars per share)   $ 9.11
Performance Shares    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted in period (in shares) 2,561,275  
Performance Shares, Market Conditions    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted in period (in shares) 1,116,323  
Granted, weighted average grant date fair value (in dollars per share) $ 5.67  
Equity-based compensation expense (benefit) $ 6.3  
Performance Shares, AEBITDA Performance    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted in period (in shares) 1,444,952  
Granted, weighted average grant date fair value (in dollars per share) $ 10.90  
Equity-based compensation expense (benefit) $ 15.8